Wall Street is positive on Sutro Biopharma Inc (STRO). On average, analysts give Sutro Biopharma Inc a Strong Buy rating. The average price target is $19, which means analysts expect the stock to increase by 163.16% over the next twelve months.
That average ranking earns Sutro Biopharma Inc an Analyst Rating of 81, which is better than 81% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected.
InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.
What's Happening With Sutro Biopharma Inc Stock Today?
Sutro Biopharma Inc (STRO) stock is lower by -0.28% while the S&P 500 is higher by 0.76% as of 11:30 AM on Monday, Jun 29. STRO has fallen -$0.02 from the previous closing price of $7.24 on volume of 218,981 shares. Over the past year the S&P 500 has gained 2.28% while STRO has fallen -38.55%. STRO lost -$2.65 per share the over the last 12 months.